<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077297</url>
  </required_header>
  <id_info>
    <org_study_id>AC-051-206</org_study_id>
    <nct_id>NCT01077297</nct_id>
  </id_info>
  <brief_title>Tezosentan in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the
      Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With
      Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin
      Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow recruitment, the study was prematurely discontinued
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PVR from Baseline to 30 minutes expresses as percent of the Baseline value.</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean right arterial pressure (mRAP) from Baseline to 30 minutes</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mPAP from Baseline to 30 min</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total pulmonary resistance (TPR) from Baseline to 30 min</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PCWP from Baseline to 30 min</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output (CO) from Baseline to 30 min</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac index (CI) from Baseline to 30 min</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Tezosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tezosentan</intervention_name>
    <description>single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg</description>
    <arm_group_label>Tezosentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Male and female patients 18 years of age or older

          3. Patients with PAH according to one of the following subgroups of the Venice
             Classification Group 1:

               -  Idiopathic (iPAH), or

               -  Familial/heritable (FPAH), or

               -  Associated (APAH) with collagen vascular disease

          4. Modified NYHA functional class II-III

          5. Documented hemodynamic diagnosis of PAH by right heart catheterization at Baseline:

               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

               -  Resting mean PVR ≥ 240 dyn•s•cm-5 and

               -  Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg

        Exclusion Criteria:

          1. Patients with PAH in Venice Classification Groups 2-5, and PAH Group 1 subgroups not
             covered by inclusion criterion no. 3

          2. Hypotensive patients (systemic systolic blood pressure &lt; 100 mmHg)

          3. Patients with body weight &lt; 50 kg (110 lbs)

          4. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

          5. Patients with clinically significant chronic renal insufficiency (serum creatinine &gt;
             2.5mg/dL / 221µmol/L)

          6. Patients who have received any endothelin receptor antagonist (ERA) and/or any
             phosphodiesterase-5 (PDE-5) inhibitor within 28 days of Baseline

          7. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
             treprostinil, iloprost) within 28 days of Baseline

          8. Patients who have received any investigational drugs within 28 days of Baseline

          9. Patients who have received cyclosporine A or tacrolimus within 28 days of Baseline

         10. Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with the study

         11. Life expectancy less than 12 months

         12. Females who are lactating or pregnant or females who are not using a reliable method
             of birth control (failure rate less than 1% per year) during the study and for at
             least one month after study drug intake

         13. Known hypersensitivity to any of the excipients of the drug formulation

         14. Patients with positive response to vasoreactivity test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabet Lindberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Béclère</name>
      <address>
        <city>Paris</city>
        <state>Clamart</state>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel, Clinic of Pneumology</name>
      <address>
        <city>Basel</city>
        <zip>CH - 4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

